Tyme Ticks On With Mid-Stage Development Of A Broad Cancer Therapy
Executive Summary
The small biotech presented positive interim data from a Phase II trial testing its lead candidate SM-88 in prostate cancer at ESMO and is gearing up to initiate a trial in pancreatice cancer.
You may also be interested in...
Deal Watch: Early 2020 Deal-Making Boom Starts With Third Bayer/Evotec R&D Alliance
The JP Morgan conference uptick in biopharma deal-making has begun with more than 20 deals announced this week, including the latest Bayer/Evotec partnership and Pfizer’s cancer tie-up with eFFECTOR.
Q3 Headwinds For Pharma Could Dampen A Continued Rally
COVID-19 disruptions, less favorable currency and the shadow of drug price reform could mean more headwinds for pharma during this S&E period after a strong Q2.
Under The Shadow Of Drug Price Reform, US Tax Policies Still Challenge Pharma
Congress is considering legislation that would reverse some of the Trump administration's friendly corporate tax policies, presenting another challenge to the biopharmaceutical industry.